France vs Mongolia: Pneumococcal conjugate second or third-dose vaccines (PCVc)
France
96.0%
in 2025
Mongolia
96.0%
in 2025
France rank
27th
Mongolia rank
27th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- France
- Mongolia
How they compare
France currently reports 96.0% against 96.0% in Mongolia, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Mongolia ahead.
France ranks 27th and Mongolia ranks 27th of 194 countries.
France has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | France | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 90.5% | 8.8% | 81.7% | France |
| 2020s | 95.7% | 94.8% | 0.8% | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), France or Mongolia?
- France, at 96.0% against 96.0% in Mongolia as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between France and Mongolia?
- 0.0%, with France ahead.
- How many years of comparable data are there for France and Mongolia?
- 18 years are reported by both, from 2008 to 2025.
- How do France and Mongolia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- France ranks 27th and Mongolia ranks 27th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.